# Johnson & Johnson (JNJ) is a global healthcare leader dedicated to advancing medical innovation and improving patient outcomes.

*biotech · news · 2026-05-04 · Barchart*

## Key points

- Johnson & Johnson raised its fiscal 2026 guidance, projecting adjusted EPS of $11.45-$11.65.
- Q1 2024 sales grew 9.9% year-over-year to $24.1 billion, beating consensus by 2.6%.
- Despite higher sales, adjusted EPS declined 2.5% to $2.70 in Q1 but exceeded estimates.
- Johnson & Johnson has outperformed both the S&P 500 and XLV over the past 52 weeks.
- The consensus analyst price target of $259.92 implies a 14.7% upside from current levels.

**Companies:** Johnson & Johnson
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1686268/are-wall-street-analysts-bullish-on-johnson-johnson-stock)

---

Canonical: https://newsio.io/n/3569129d-df34-4cdf-a25f-90f99802c669/johnson-johnson-jnj-is-a-global-healthcare-leader-dedicated-to-advancing-medical
Summarized by Newsio from Barchart. https://newsio.io/how-it-works